Last reviewed · How we verify
Strattera (atomoxetine)
Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in key attention and executive function circuits.
Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in key attention and executive function circuits. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | Strattera (atomoxetine) |
|---|---|
| Also known as | Strattera |
| Sponsor | Massachusetts General Hospital |
| Drug class | Selective norepinephrine reuptake inhibitor (NRI) |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
By blocking the norepinephrine transporter (NET), atomoxetine prevents the reabsorption of norepinephrine from the synaptic cleft, leading to increased norepinephrine availability in the prefrontal cortex and other brain regions involved in attention and impulse control. This mechanism differs from stimulant medications and makes it a non-stimulant option for ADHD treatment.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Nausea
- Decreased appetite
- Insomnia
- Dizziness
- Fatigue
- Mood swings
- Increased heart rate
Key clinical trials
- Atomoxetine and DAW2022 on OSA Severity (PHASE1, PHASE2)
- Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (PHASE3)
- Atomoxetine and Executive Function in PTSD (PHASE4)
- TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (EARLY_PHASE1)
- A Novel Pharmacological Therapy for Obstructive Sleep Apnea (PHASE2)
- Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea (PHASE1, PHASE2)
- Endotype DIrected Treatment for OSA in Down Syndrome (PHASE4)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Strattera (atomoxetine) CI brief — competitive landscape report
- Strattera (atomoxetine) updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI